Drug Insights

Making the Most Out of Synapse: Searching for Pantoprazole

1 February 2024
2 min read

Pantoprazole is a small molecule medicine classed as a proton pump inhibitor, which means it reduces the amount of acid generated in the stomach. Takeda Pharmaceutical Co., Ltd. authorized this drug for the first time in January 1994. Pantoprazole is exceptionally efficient in treating disorders such as peptic ulcer bleeding, which is characterized by excessive acid output, resulting in stomach lining erosion. It is also used to treat fasting when acid secretion can cause pain and bleeding. Generally speaking, Pantoprazole is well-tolerated and has minimal adverse effects, making it a common therapy choice for acid-related diseases. Click on the image below to begin the exploration journey of Pantoprazole through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Synapse Simplified: How to Find Ivermectin Information
Drug Insights
2 min read
Synapse Simplified: How to Find Ivermectin Information
1 February 2024
Ivermectin, a small molecule drug, operates as a modulator of the glutamate-gated chloride channel, an action that forms the basis of its pharmacological activity.
Read →
PharmAbcine Begins Early-Stage PMC-309/KEYTRUDA Trial for Severe Solid Cancers
Latest Hotspot
3 min read
PharmAbcine Begins Early-Stage PMC-309/KEYTRUDA Trial for Severe Solid Cancers
1 February 2024
PharmAbcine Initiates Dosing in Early-Stage Study for PMC-309 with KEYTRUDA (pembrolizumab) in Subjects Facing Severe Solid Cancers.
Read →
A Complete Guide to Searching Prednisone on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Prednisone on Synapse
1 February 2024
Prednisone is a widely-used corticosteroid drug for treating inflammatory conditions such as allergies, arthritis, and asthma, working by suppressing the immune system to reduce inflammation.
Read →
Harbor BioMed Confirms U.S. Approval to Begin Trials with HBM9027
Latest Hotspot
3 min read
Harbor BioMed Confirms U.S. Approval to Begin Trials with HBM9027
1 February 2024
Harbour BioMed has been granted FDA approval to initiate human trials for their bispecific antibody, HBM9027, in the U.S.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.